Mera Pharmaceuticals, Inc.
MRPI · OTC
10/31/2011 | 7/31/2011 | 4/30/2011 | 1/31/2011 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -26.4% | -0.5% | 35% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 96.5% | 99.7% | 88.3% | 94.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -162% | -23.1% | -43.5% | -61.1% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -159.9% | -18.1% | -40.2% | -53.7% |
| EPS | -0 | -0 | -0.01 | -0 |
| % Growth | -595.6% | 99.7% | -9,900% | – |
| EPS Diluted | -0 | -0 | -0.01 | -0 |
| Weighted Avg Shares Out | 553 | 548 | 548 | 548 |
| Weighted Avg Shares Out Dil | 553 | 548 | 548 | 548 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -158.7% | -18.3% | -42% | -52.2% |